Microvessel Density (MVD) in Patients with Osteosarcoma: A Systematic Review and Meta-Analysis

References

• Ottaviani G, Jaffe N. The epidemiology of osteosarcoma [Internet]. In: Cancer Treatment and Research. 2009; [cited 2018 Nov 8]. 3–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20213383
   PubMedGoogle Scholar
• Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer [Internet]. 2009;115(7):1531–1543. doi:10.1002/cncr.24121.
   PubMed Web of Science ®Google Scholar
• Meazza C, Scanagatta P. Metastatic osteosarcoma: a challenging multidisciplinary treatment. Expert Rev Anticancer Ther. 2016;16(5):543–556. doi:10.1586/14737140.2016.1168697.
   PubMed Web of Science ®Google Scholar
• Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018;18(1):39–50. doi:10.1080/14737140.2018.1413939.
   PubMed Web of Science ®Google Scholar
• Evola FR, Costarella L, Pavone V, Caff G, Cannavò L, Sessa A, et al. Biomarkers of osteosarcoma, chondrosarcoma, and Ewing sarcoma. Front Pharmacol. 2017;8:150–28439237. doi:10.3389/fphar.2017.00150.
   PubMed Web of Science ®Google Scholar
• Kim YH, Goh TS, Lee CS, Oh SO, Kim J, Il, Jeung SH, Pak K. Prognostic value of microRNAs in osteosarcoma: A meta-analysis. Oncotarget [Internet]. 2017;8(5):8726–8737. doi:10.18632/oncotarget.14429.
   PubMedGoogle Scholar
• Fu Y, Lan T, Cai H, Lu A, Yu W. Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma. Medicine (Baltimore)). 2018;97(19):e0741. doi:10.1097/MD.0000000000010741.
   PubMed Web of Science ®Google Scholar
• Wang C, Jing J, Cheng L. Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma. Invest New Drugs. 2018;36(6):1116–1132. doi:10.1007/s10637-018-0624-7.
   PubMed Web of Science ®Google Scholar
• Otoukesh B, Boddouhi B, Moghtadaei M, Kaghazian P, Kaghazian M. Novel molecular insights and new therapeutic strategies in osteosarcoma. Cancer Cell Int. 2018;18(1):158–30349420. doi:10.1186/s12935-018-0654-4.
   PubMedGoogle Scholar
• Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Cancer [Internet]. 2006;106(5):1154–1161. doi:10.1002/cncr.21724.
   PubMed Web of Science ®Google Scholar
• Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag. 2006;2(3):213–219.
   PubMedGoogle Scholar
• Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 2003;9(15):5442–5453.
   PubMed Web of Science ®Google Scholar
• Xie L, Ji T, Guo W. Anti-angiogenesis target therapy for advanced osteosarcoma (Review). Oncol Rep. 2017;38(2):625–636. doi:10.3892/or.2017.5735.
   PubMed Web of Science ®Google Scholar
• Quan GMY, Choong PFM. Anti-angiogenic therapy for osteosarcoma. Cancer Metastasis Rev. 2007;25(4):707–713. doi:10.1007/s10555-006-9031-1.
   Web of Science ®Google Scholar
• Lammli J, Fan M, Rosenthal HG, Patni M, Rinehart E, Vergara G, et al. Expression of vascular endothelial growth factor correlates with the advance of clinical osteosarcoma. Int Orthop. 2012;36(11):2307–2313. doi:10.1007/s00264-012-1629-z.
   PubMed Web of Science ®Google Scholar
• Giner F, López-Guerrero JA, Machado I, García-Casado Z, Peydró-Olaya A, Llombart-Bosch A. The early stages of tumor angiogenesis in human osteosarcoma: a nude mice xenotransplant model. Virchows Arch. 2015;467(2):193–201. doi:10.1007/s00428-015-1791-y.
   PubMed Web of Science ®Google Scholar
• Yang J, Yang D, Sun Y, Sun B, Wang G, Trent JC, et al. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer [Internet. 2011;117(21):4925–4938. doi:10.1002/cncr.26116.
   PubMed Web of Science ®Google Scholar
• Abdeen A, Chou AJ, Healey JH, Khanna C, Osborne TS, Hewitt SM, et al. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer [Internet. 2009;115(22):5243–5250. doi:10.1002/cncr.24562.
   PubMed Web of Science ®Google Scholar
• Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1–8. doi:10.1056/NEJM199101033240101.
   PubMed Web of Science ®Google Scholar
• He L, Wang Q, Zhao X. Microvessel density as a prognostic factor in ovarian cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2015;16(3):869–874.
   PubMedGoogle Scholar
• Hu X, Liu H, Ye M, Zhu X. Prognostic value of microvessel density in cervical cancer. Cancer Cell Int. 2018;18(1):152–30305802. doi:10.1186/s12935-018-0647-3.
   PubMedGoogle Scholar
• Ma G, Zhang J, Jiang H, Zhang N, Zhu Y, Deng Y, Zhou Q. Microvessel density as a prognostic factor in esophageal squamous cell cancer patients. Medicine (Baltimore)). 2017;96(29):e7600. doi:10.1097/MD.0000000000007600.
   PubMed Web of Science ®Google Scholar
• Perivoliotis K, Ntellas P, Dadouli K, Koutoukoglou P, Ioannou M, Tepetes K. Microvessel density in patients with cutaneous melanoma: an up-to-date systematic review and meta-analysis. J Skin Cancer. 2017;2017:2049140–16. doi:10.1155/2017/2049140.
   PubMedGoogle Scholar
• Kreuter M, Bieker R, Bielack SS, Auras T, Buerger H, Gosheger G, et al. Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res. 2004;10(24):8531–8537. doi:10.1158/1078-0432.CCR-04-0969.
   PubMed Web of Science ®Google Scholar
• Ek ETH, Ojaimi J, Kitagawa Y, Choong PFM. Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma? Oncol Rep. Oncol Rep. 2006;16(1):17–23.
   PubMed Web of Science ®Google Scholar
• Kubo T, Shimose S, Fujimori J, Arihiro K, Ochi M. Diversity of angiogenesis among malignant bone tumors. Mol Clin Oncol. 2013;1(1):131–136. doi:10.3892/mco.2012.11.
   PubMedGoogle Scholar
• Li Z, Jia M, Wu X, Cui J, Pan A, Li L. Overexpression of Trps1 contributes to tumor angiogenesis and poor prognosis of human osteosarcoma. Diagn Pathol. 2015;10(167):167. doi:10.1186/s13000-015-0401-2.
   PubMedGoogle Scholar
• Luo W, Shao C, Li N, Zhang F, Guo S, Duan Z, et al. Expression of epidermal growth factor-like domain 7 correlates with clinicopathological features of osteosarcoma. Am J Transl Res. 2015;7(7):1236–1245.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’connell D, Petersen J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Department of Epidemiology and Community Medicine. University of Ottawa, Canada. Univ Ottawa, Canada Available www ohri ca/programs/clinical_epidemiology/oxford asp 2011.
   Google Scholar
• Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statist Med. 1998;17(24):2815–2834. doi:10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8(1):16. doi:10.1186/1745-6215-8-16.
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. doi:10.1186/1471-2288-12-9.
   PubMed Web of Science ®Google Scholar
• Bormann I. DigitizeIt 2.2. Digitizer Software—Digitize a Scanned Graph or Chart Into (x, y). Data. 2016. http://www.digitizeit.de.
   PubMedGoogle Scholar
• Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13. doi:10.1186/1471-2288-5-13.
   PubMedGoogle Scholar
• Jiang X, Shan J, Dai N, Zhong Z, Qing Y, Yang Y, et al. Apurinic/apyrimidinic endonuclease 1 regulates angiogenesis in a transforming growth factor β-dependent manner in human osteosarcoma. Cancer Sci. 2015;106(10):1394–1401. doi:10.1111/cas.12763.
   PubMed Web of Science ®Google Scholar
• Kunz P, Fellenberg J, Moskovszky L, Sápi Z, Krenacs T, Machado I, et al. Improved survival in osteosarcoma patients with atypical low vascularization. Ann Surg Oncol. 2015;22(2):489–496. doi:10.1245/s10434-014-4001-2.
   PubMed Web of Science ®Google Scholar
• Salah S, Ahmad R, Sultan I, Yaser S, Shehadeh A. Osteosarcoma with metastasis at initial diagnosis: Current outcomes and prognostic factors in the context of a comprehensive cancer center. Mol Clin Oncol. 2014;2(5):811–816. doi:10.3892/mco.2014.325.
   PubMedGoogle Scholar
• Zhang Y, Yang J, Zhao N, Wang C, Kamar S, Zhou Y, et al. Progress in the chemotherapeutic treatment of osteosarcoma. Oncol Lett. 2018 [cited 2018;16(5):6228–6237. doi:10.3892/ol.2018.9434.
   PubMed Web of Science ®Google Scholar
• He H, Ni J, Huang J. Molecular mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett. 2014;7(5):1352–1362. doi:10.3892/ol.2014.1935.
   PubMed Web of Science ®Google Scholar
• Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011;17(11):1359–1370. doi:10.1038/nm.2537.
   PubMed Web of Science ®Google Scholar
• Shahi PK, Pineda IF. Tumoral angiogenesis: review of the literature. Cancer Invest [Internet]. 2008;26(1):104–108. doi:10.1080/07357900701662509.
   PubMed Web of Science ®Google Scholar
• Benckert C, Thelen A, Cramer T, Weichert W, Gaebelein G, Gessner R, Jonas S. Impact of microvessel density on lymph node metastasis and survival after curative resection of pancreatic cancer. Surg Today. 2012;42(2):169–176. doi:10.1007/s00595-011-0045-0.
   PubMed Web of Science ®Google Scholar
• Nowak A, Grzegrzolka J, Paprocka M, Piotrowska A, Rys J, Matkowski R, Dziegiel P. Nestin-positive microvessel density is an independent prognostic factor in breast cancer. Int J Oncol. 2017;51(2):668–676. doi:10.3892/ijo.2017.4057
   PubMed Web of Science ®Google Scholar
• Tomlinson J, Barsky SH, Nelson S, Singer S, Pezeshki B, Lee MC, et al. Different patterns of angiogenesis in sarcomas and carcinomas. Clin Cancer Res. 1999;5(11):3516–3522.
   PubMed Web of Science ®Google Scholar
• Verrecchia F, Rédini F. Transforming growth factor-β signaling plays a pivotal role in the interplay between osteosarcoma cells and their microenvironment. Front Oncol. 2018 8:133. doi:10.3389/fonc.2018.00133.
   PubMed Web of Science ®Google Scholar
• Hong G, Kuek V, Shi J, Zhou L, Han X, He W, et al. EGFL7: Master regulator of cancer pathogenesis, angiogenesis and an emerging mediator of bone homeostasis. J Cell Physiol. 2018 [cited 2018;233(11):8526–8537. doi:10.1002/jcp.26792.
   PubMed Web of Science ®Google Scholar
• Wen J, Xu Z, Li J, Zhang Y, Fan W, Wang Y, et al. Decreased WWOX expression promotes angiogenesis in osteosarcoma. Oncotarget [Internet]. 2017;8(37):60917–60932. doi:10.18632/oncotarget.17126.
   PubMedGoogle Scholar
• Jian YK, Zhu HY, Wu XL, Li B. Thrombospondin-1 triggers osteosarcoma cells metastasis and tumor angiogenesis. Oncol Res Featur Preclin Clin Cancer Ther [Internet]. 2018;27(2):211–218. doi:10.3727/096504018X15208993118389.
   Google Scholar
• Wang L-H, Tsai H-C, Cheng Y-C, Lin C-Y, Huang Y-L, Tsai C-H, et al. CTGF promotes osteosarcoma angiogenesis by regulating miR-543/angiopoietin 2 signaling. Cancer Lett. 2017;391:28–37. doi:10.1016/j.canlet.2017.01.013.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Zhu Y, Deng Z, Long H, Zhang S, Chen X. VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma. Surg Oncol. 2011;20(1):13–19. doi:10.1016/j.suronc.2009.09.002.
   PubMed Web of Science ®Google Scholar
• Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000;6(2):572–577.
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Wei M. Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis. Tumour Biol. 2014;35(3):1745–1749. doi:10.1007/s13277-014-1692-8.
   PubMedGoogle Scholar
• Ouyang Y, Li H, Bu J, Li X, Chen Z, Xiao T. Hypoxia-inducible factor-1 expression predicts osteosarcoma patients’ survival: a meta-analysis. Int J Biol Markers. 2016;31(3):e229–e234. doi:10.5301/jbm.5000216.
   PubMed Web of Science ®Google Scholar
• Mikulić D, Ilić I, Cepulić M, Orlić D, Giljević JS, Fattorini I, Seiwerth S. Tumor angiogenesis and outcome in osteosarcoma. Pediatr Hematol Oncol. 2004;21(7):611–619.
   PubMed Web of Science ®Google Scholar
• West CC, Brown NJ, Mangham DC, Grimer RJ, Reed MWR. Microvessel density does not predict outcome in high grade soft tissue sarcoma. Eur J Surg Oncol. 2005;31(10):1198–1205. doi:10.1016/j.ejso.2005.04.012.
   PubMed Web of Science ®Google Scholar
• Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer. 2002;38(12):1564–1579.
   PubMed Web of Science ®Google Scholar